Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, 3508 GA Utrecht, The Netherlands. m.j.j.mangen@uncutrecht.nl
This study assessed whether the inclusion of two rotavirus (RV) vaccines in the Dutch national immunization programme is cost-effective. Costs and outcomes in unvaccinated and vaccinated populations are compared for a time period of 20 years. In the baseline, assuming competitive market forces in relation to vaccine costs, Rotarix is more cost-effective than RotaTeq, resulting in a cost-utility ratio (CUR) of euro 53,000 per DALY (third payer perspective) and euro 49,000 per DALY (societal perspective), but both considered as being not cost-effective. Vaccine-related costs, annual epidemic-size, and indirect protection are the major factors that determine cost-effectiveness of RV vaccination.
Copyright 2010 Elsevier Ltd. All rights reserved.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on